Related Experiment Video
Updated: Apr 5, 2026
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Drug therapies for metastatic castration-resistant prostate cancer
Ehab El-Bahesh1, Antoine Finianos1, Abeer Alfaraj2
1INOVA Comprehensive Cancer & Research Institute, 8505 Arlington Blvd, Ste 100, Fairfax, VA 22031, USA.
Abstract:
Management of metastatic castration-resistant prostate cancer has changed markedly over the last decade with major shifts in the treatment paradigm, although ultimately still will progress despite currently available therapies. The sequencing or combination of these agents is an area of active investigation, since definitive prospective randomized trials to define the optimal choice of drug sequence have yet to be done or resulted. This article will highlight pivotal trials for currently approved therapies for metastatic castration-resistant prostate cancer and a suggestion for sequencing of these agents, as well as highlighting investigations using novel therapies for advanced prostate cancer.
Insights
Treatment for metastatic castration-resistant prostate cancer has evolved, but disease progression remains a challenge. This review discusses pivotal trials and suggests optimal sequencing for approved therapies and novel treatments in advanced prostate cancer.
Area of Science:
- Oncology
- Urology
- Medical Oncology
Background:
- Metastatic castration-resistant prostate cancer (mCRPC) management has significantly evolved.
- Despite advances, mCRPC ultimately progresses with current therapies.
- Optimal sequencing and combination of mCRPC agents require further investigation.
Purpose of the Study:
- To review pivotal trials of approved therapies for mCRPC.
- To suggest a sequencing strategy for current mCRPC agents.
- To highlight novel therapeutic investigations for advanced prostate cancer.
Main Methods:
- Literature review of key clinical trials in mCRPC.
- Analysis of treatment paradigms and outcomes.
- Discussion of emerging therapeutic strategies.
Main Results:
- Several therapies are approved for mCRPC, demonstrating improved outcomes.
- Definitive trials for optimal drug sequencing are limited.
- Novel agents are under investigation for advanced prostate cancer.
Conclusions:
- Current mCRPC therapies offer improved but not definitive disease control.
- Evidence-based sequencing of mCRPC treatments is an active area of research.
- Novel therapies hold promise for future mCRPC management.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:57Targeted Cancer Therapies
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:49Cancer Therapies
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:56Treatment Resistent Cancers